Genzyme Corp. ‘s financial history is unusual compared to most biotech companies. This case is employed, together with the product, the sequence of financing of Genzyme – adopted market and corporate development strategies by Henri Termeer, Genzyme’s CEO. As such, the case allows students to evaluate the order of the financing as “program” rather than a series of independent offers and consider them in light of the company’s strategy.

Genzyme Corp. ‘s financial history is unusual compared to most biotech companies. This case is employed, together with the product, the sequence of financing of Genzyme – adopted market and corporate development strategies by Henri Termeer, Genzyme’s CEO. As such, the case allows students to evaluate the order of the financing as “program” rather than a series of independent offers and consider them in light of the company’s strategy.
«Hide

from
Timothy A. Luehrman,
Andrew D. Regan
Source: Harvard Business School
18 pages.
Publication Date: Jul 20, 1993. Prod #: 294005-PDF-ENG
Genzyme Corp.: A Financing History HBR case solution